Prakiraan pendapatan perusahaan: G1 Therapeutics Inc. (GTHX)

G1 Therapeutics (GTHX) - logo korporat

G1 Therapeutics, Inc. (GTHX) management's strategy to increase royalty payments relies on licensing bone marrow protective agents in Europe and Asia. The company's future sales levels visualize this trend, where 0.06 represents the current metric. Business stability is maintained through strict temperature control during the delivery of drugs to clinics, ensuring an uninterrupted supply for patients.

Volume dodolan sing dikarepake perusahaan: G1 Therapeutics, Inc. (GTHX) kanggo 04.07.2022 - 28.09.2024

Ringkesan rincian data analitis G1 Therapeutics (GTHX)

- nilai saham lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
Pambiji fundamental:G1 Therapeutics GTHX
Sampel barang g1therapeutics.com

This metric measures expected cash inflows adjusted for operational risks and the cost of capital. An analysis of product sales expectations reveals the gap between actual performance and management targets. The metric assesses the market capitalization of future revenues through the lens of discounting. For G1 Therapeutics, Inc. (GTHX), this reflects the monetization of an exclusive drug. The high cost of therapy in the absence of analogs ensures steady growth of this indicator.

Pesaing wigati

Prakiraan pendapatan perusahaan Incyte Pharma (INCY)|Prakiraan pendapatan perusahaan HCM (Hutchison MediPharma)|Prakiraan pendapatan perusahaan Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc - Prakiraan pendapatan perusahaan|MNPR - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Inhibrx Biosciences|IMAB: Prakiraan volume dodolan|Prakiraan dodolan perusahaan Fennec Pharmaceuticals Inc FENC|Volume dodolan mangsa ngarep perusahaan HRTX|Volume dodolan sing dikarepake perusahaan Nuvectis Pharma, Inc. NVCT|Volume dodolan mangsa ngarep perusahaan CHRS (Coherus BioSciences, Inc)|CRBP (Corbus Pharmaceuticals Holdings) - Pendapatan mangsa ngarep perusahaan|Cardiff Oncology - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan BYSI (BeyondSpring)|BioAtla - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan LIXT (Lixte Biotechnology Holdings)|CTXR: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan cellectar.com (CLRB)|Prakiraan pendapatan perusahaan BioLineRx|CANF: Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan APRE|Prakiraan volume dodolan Kazia Therapeutics Ltd (KZIA)|Prakiraan pendapatan perusahaan Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Pendapatan sing dikarepake perusahaan|CMRX: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan Cyclacel|Kronos Bio Inc (KRON) - Prakiraan pendapatan perusahaan|Kintara (KTRA) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan Oncternal Therapeutics, Inc.|Volume dodolan sing dikarepake perusahaan portagebiotech.com PRTG